This issue chosen by the Editor of Intestinal Research is “Influence of anti-tumor necrosis factor-alpha (anti-TNF-α) therapy on pregnant inflammatory bowel disease (IBD) women and their children’s immunity” performed by Lee KE, et al. Although previous studies have shown conflicting results on the safety of anti-TNF-α therapy on IBD women during pregnancy, the majority of studies suggested that the use of anti-TNF-α agents was not associated with any increase of miscarriage and neonatal complications. This study showed that all 18 IBD women who delivered their child while receiving anti-TNF-α treatments maintained remission without any significant complications. Of these, 12 children followed the regular vaccination schedules for hepatitis B virus. Although 4 out of the 12 children (33.3%) were anti-HBs negative, all those 4 children demonstrated seroconversion after the 1 booster vaccination. None of 8 children who had live vaccinations before 6 months after birth had any specific side effects. Read more about the influence of anti-TNF-α therapy on pregnant IBD women and their children’s immunity. In addition to this article, read other related articles listed below about maternal and fetal outcomes in pregnant women with IBD. Best regards,